ANTIGENICS EXPANDS GLAXOSMITHKLINE PACT AND ELAN CLIMBS ON ABBOTT/ASTRAZENECA LICENSE DEAL

A A

Pharmaceuticals Instruments industry news provided by Financial News USA. Biotechnology company Antigenics Inc. said Monday it has expanded a license and supply agreement with a unit of GlaxoSmithKline Plc. (NYSE:GSK) Under the expanded agreement, GlaxoSmithKline Biologicals will purchase part of its supply requirements for the adjuvant QS-21 from Antigenics through 2014. Antigenics company will transfer manufacturing technologies to GlaxoSmithKline.

Financial News USA (http://www.financialnewsusa.com/release.php?rlsid=5606)